Table 5.
Cost-effectiveness results by subgroup (UK NHS perspective)
| Subgroup | Incremental costs (£) | Incremental QALYs | ICER (£/QALY gained) |
|---|---|---|---|
| General population | 37.88 | 0.0086 | 4,386 |
| Previously treated | 38.07 | 0.0099 | 3,836 |
| Dissatisfied because of lack of efficacy | 40.27 | 0.0091 | 4,446 |
| Dissatisfied because of adverse events | 28.37 | 0.0186 | 1,528 |
| Incontinent | 32.36 | 0.0124 | 2,620 |
| Elderly | 35.19 | 0.0061 | 5,736 |
| Treatment naïve | 40.27 | 0.0076 | 5,315 |
| Women | 37.73 | 0.0122 | 3,091 |
| Men | 43.96 | 0.0011 | 38,708 |
ICER incremental cost-effectiveness ratio, QALY quality-adjusted life-year